🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check my latest publication kidney360 journals.lww.com/kidney360/full…

I am totally with you

Diabetic Kidney Disease (DKD) ca. 2025 from Elsevier BeanQueen Gaddy Mohamed E. Elrggal Hector Madariaga, MD FASN 🇲🇽 Gates Colbert, MD #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/39753456/

A great group effort on describing the latest large trial landscape for treatment in diabetic kidney disease.

Despite my ranking, I am still getting both winners at the finals. #nephmadness NephMadness

Despite my ranking, I am still getting both winners at the finals. #nephmadness NephMadness

Podcast--Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury edhub.ama-assn.org/jn-learning/au… Shruti Gupta

Looking to improve kidney care in your region? 🌍 The ISN offers practical #OpenAccess toolkits for health professionals, policymakers & advocates—supporting prevention, diagnosis & treatment across all settings: lite.spr.ly/6005HyAB 🧵

7️⃣ ISN-ACT Clinical Trials Toolkit: A global resource for nephrologists and researchers of all experience levels, offering guidance to start or join clinical trials, regardless of local resources: lite.spr.ly/6001Hy21

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases academic.oup.com/ndt/article/39… An amazing article from the high impact articles published NDT Hans-Joachim Anders

Tailored management strategies for IgA nephropathy based on clinical presentations 🆓doi.org/10.1093/ndt/gf… This Review proposes therapeutic algorithms to guide treatment decisions in different clinical scenarios while highlighting gaps in current research

May 2025 ASN Publications Kidney News kidneynews.org/view/journals/… Preeclampsia and Rare Genetic Variants in the Terminal Complement System Shreepriya Mangalgi Silvi Shah, MD, MS

Low-renin hypertension despite the use of ACE inhibitors or ARBs is almost certainly a form of primary aldosteronism. Thrilled to know that our group's work is the featured article in this month's issue of hypertension ! ahajournals.org/doi/full/10.11… Anand Vaidya Jen Brown

Now open access in the June edition of NDT Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA 🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD. academic.oup.com/ndt/article/40…

Kidney News July 2025 ASN Publications Clinical Practice Guidelines for Genetic Testing in ADPKD Neera K. Dahl Pranav Garimella and Fouad T. Chebib kidneynews.org/view/journals/…

Sparsentan: a dual endothelin and angiotensin II receptor antagonist (DEARA) approved for IgA nephropathy (IgAN) ca 2025 from Gates Colbert, MD Hector Madariaga, MD FASN 🇲🇽 BeanQueen Gaddy Mohamed E. Elrggal #Nephpearls tandfonline.com/doi/full/10.10…

Read this piece from the ERAKI working group at the NDT regarding the results of the DEFENDER trial published last August JAMA academic.oup.com/ndt/article/40…

Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies: ✅ Empagliflozin (#EMPEROR) ✅ Dapagliflozin (#DELIVER) ✅ Sotagliflozin (#SOLOISTWHF) ✅ Sacubitril/Valsartan (#PARAGONHF) ✅ Finerenone (#FINEARTSHF)

Our recent review

Large volume paracentesis - check out the total volume drained at the end!